Cargando…

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study

Objectives: HCV shows complex interactions with lipid metabolism. Our aim was to examine total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) changes in HIV/HCV coinfected patients, after achieving sustained virological response (SVR), according to different HCV genotypes and speci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spaziante, Martina, Taliani, Gloria, Marchetti, Giulia, Tavelli, Alessandro, Lichtner, Miriam, Cingolani, Antonella, Cicalini, Stefania, Biliotti, Elisa, Girardi, Enrico, Antinori, Andrea, Puoti, Massimo, d’Arminio Monforte, Antonella, Cozzi-Lepri, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310285/ https://www.ncbi.nlm.nih.gov/pubmed/34372608 http://dx.doi.org/10.3390/v13071402

Ejemplares similares

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
por: d'Arminio Monforte, Antonella, et al.
Publicado: (2017)

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
por: Malagnino, Vincenzo, et al.
Publicado: (2020)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study
por: Marchetti, Giulia, et al.
Publicado: (2014)

Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort
por: Cingolani, A, et al.
Publicado: (2015)

High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort
por: Squillace, Nicola, et al.
Publicado: (2016)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort
por: Nozza, Silvia, et al.
Publicado: (2017)

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2016)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?
por: Shanyinde, Milensu, et al.
Publicado: (2019)

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2020)

Reply to Manfredi
por: Lichtner, Miriam, et al.
Publicado: (2015)

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus
por: Mussini, Cristina, et al.
Publicado: (2015)

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era
por: Madeddu, Giordano, et al.
Publicado: (2021)

Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss
por: Mussini, Cristina, et al.
Publicado: (2021)

Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy
por: Nozza, Silvia, et al.
Publicado: (2021)

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study
por: Mussini, Cristina, et al.
Publicado: (2018)

Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy
por: Cingolani, Antonella, et al.
Publicado: (2022)

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients
por: Marchetti, Giulia, et al.
Publicado: (2012)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population
por: Cingolani, Antonella, et al.
Publicado: (2017)

Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice
por: Garagiola, Elisabetta, et al.
Publicado: (2020)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy
por: Madeddu, Giordano, et al.
Publicado: (2014)

Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients
por: Saracino, Annalisa, et al.
Publicado: (2018)

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord
por: Smit, Colette, et al.
Publicado: (2015)

A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy
por: Bai, Francesca, et al.
Publicado: (2021)

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
por: Di Biagio, Antonio, et al.
Publicado: (2016)

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
por: Costarelli, Silvia, et al.
Publicado: (2016)

Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy
por: Bandera, Alessandra, et al.
Publicado: (2015)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study
por: Smit, Mikaela, et al.
Publicado: (2017)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
por: Taramasso, Lucia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lji80pd2iaprjuq4jmv21vd2qa